Filtros de búsqueda

Lista de obras de Enrique M Ocio

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

artículo científico publicado en 2007

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

artículo científico publicado en 2020

6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis

scientific article published on 01 January 2007

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma.

artículo científico publicado en 2016

Aggressive primary cutaneous CD30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin

scientific article published on 07 September 2018

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

artículo científico publicado en 2017

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

artículo científico publicado en 2012

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

artículo científico publicado en 2008

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth

artículo científico publicado en 2006

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

artículo científico publicado en 2011

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

artículo científico publicado en 2016

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

artículo científico publicado en 2015

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

artículo científico publicado en 2014

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

scientific article published on 13 November 2019

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression

artículo científico publicado en 2021

CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

artículo científico publicado en 2012

CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

artículo científico publicado en 2005

Cell cycle analysis of Waldenstrom's macroglobulinemia

artículo científico publicado en 2005

Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS

artículo científico publicado en 2018

Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation

artículo científico publicado en 2006

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

artículo científico publicado en 2019

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects

artículo científico publicado en 2012

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

artículo científico publicado en 2013

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

artículo científico publicado en 2018

Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry

artículo científico publicado en 2011

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

artículo científico publicado en 2018

Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

artículo científico publicado en 2005

Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

artículo científico publicado en 2015

Filanesib for the treatment of multiple myeloma

scientific article published on 12 December 2019

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

artículo científico publicado en 2020

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

artículo científico publicado en 2018

Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia.

artículo científico publicado en 2006

Future agents and treatment directions in multiple myeloma

artículo científico publicado en 2013

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals

artículo científico publicado en 2007

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy

artículo científico publicado en 2014

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

artículo científico publicado en 2020

Immunophenotypic analysis of Waldenstrom's macroglobulinemia

artículo científico publicado en 2003

Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma

artículo científico publicado en 2005

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

artículo científico publicado en 2009

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.

artículo científico publicado en 2006

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

artículo científico publicado en 2014

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

artículo científico publicado en 2007

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

International prognostic scoring system for Waldenstrom macroglobulinemia

artículo científico publicado en 2009

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.

artículo científico publicado en 2016

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

artículo científico publicado en 2007

Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

artículo científico publicado en 2020

Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival

artículo científico publicado en 2002

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

artículo científico publicado en 2016

Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes

article

Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance

artículo científico publicado en 2007

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

artículo científico publicado en 2014

Multiple myeloma: treatment evolution

artículo científico publicado en 2012

Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case

artículo científico publicado en 2016

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

artículo científico publicado en 2018

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

artículo científico publicado en 2017

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

artículo científico publicado en 2014

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

artículo científico publicado en 2008

Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.

artículo científico publicado en 2012

Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.

artículo científico publicado en 2007

Novel generation of agents with proven clinical activity in multiple myeloma.

artículo científico

Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).

artículo científico publicado en 2006

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

artículo científico publicado en 2015

POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis

artículo científico publicado en 2022

Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

artículo científico publicado en 2020

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

scientific article published on 15 May 2019

Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis.

artículo científico publicado en 2007

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

artículo científico publicado en 2016

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

artículo científico publicado en 2014

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

artículo científico publicado en 2014

Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia

artículo científico publicado en 2011

Potent antimyeloma activity of a novel ERK5/CDK inhibitor

artículo científico publicado en 2013

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

artículo científico publicado en 2014

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

artículo científico publicado en 2017

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

artículo científico publicado en 2019

Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma

artículo científico publicado en 2020

Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study

scientific article published on 01 October 2004

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

artículo científico publicado en 2012

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

artículo científico publicado en 2017

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

artículo científico publicado en 2012

Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

artículo científico publicado en 2012

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

artículo científico publicado en 2016

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

scientific article published on 23 October 2015

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.

artículo científico publicado en 2016

The DAC system and associations with multiple myeloma.

artículo científico publicado en 2010

The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care

artículo científico publicado en 2016

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

artículo científico publicado en 2015

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

artículo científico publicado en 2011

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

artículo científico publicado en 2012

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

artículo científico publicado en 2006

The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.

artículo científico publicado en 2008

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.

artículo científico publicado en 2017

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

artículo científico publicado en 2014

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease

artículo científico publicado en 2014

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

artículo científico publicado en 2011

Treatment for patients with newly diagnosed multiple myeloma in 2015.

artículo científico

Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia

artículo científico publicado en 2006

Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia

artículo científico publicado en 2008

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia

artículo científico publicado en 2006

Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.

artículo científico publicado en 2011

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

artículo científico publicado en 2015

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda